Clinical trial · Observational
Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer
Influence of Neoadjuvant Chemoimmunotherapy on Treatment Response in Stage IIIA- N2IIIB Non-small Cell Lung Cancer
NCT06394427CI-TRIAL-00076638unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
to explore the impact of preoperative neoadjuvant immunotherapy on perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer Stage ⅢA | — | UNRESOLVED | — |
| Non-small Cell Lung Cancer Stage IIIB | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cycles of neoadjuvant therapy and duration of waiting for surgery | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- chemoimmunotherapy group 1
- description
- patients received different cycles of neoadjuvant chemoimmunotherapy
- interventionNames
- Other: cycles of neoadjuvant therapy and duration of waiting for surgery
- label
- chemoimmunotherapy group 2
- description
- the duration of before patients received surgery after neoadjuvant chemoimmunotherapy
- interventionNames
- Other: cycles of neoadjuvant therapy and duration of waiting for surgery
Primary outcomes (3)
- measure
- major pathological remission
- timeFrame
- one month
- description
- proportion of patients with no more than 10% residual viable tumor cells; patients who showed no viable tumor in the lung primary setting but lymph nodes show viable metastatic carcinoma were also classified as MPR
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria:
* Confirmed as primary lung cancer through cytology or histological examination;
* ECOG score of 0 or 1; ③ 18 years old or above;
* Received imaging examination, with a preliminary clinical staging of stage III;
* Received genetic testing and tested negative for EGFR mutations, ALK or ROS-1 fusion; ⑥ Accepting preoperative neoadjuvant immunotherapy combined with chemotherapy; ⑦ Receive surgical treatment after completion of neoadjuvant therapy; ⑧ The postoperative specimens were sent to the pathology department of our hospital for pathological testing, and a complete pathological report is available.
Exclusion Criteria:
* Patients with combined small cell lung cancer; ② Patients with severe liver/kidney dysfunction, cardiovascular disease, or systemic immune disorders;
* Accept other neoadjuvant treatments; ④ Patients participating in any clinical trial.References
Publications (0)
Data not yet available
No reference posted for this study.